Thermo Fisher (TMO) Earnings Dates, Call Summary & Reports

5,157 Followers

Earnings Data

Report Date

Jul 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

5.73

Last Year’s EPS

5.36

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 15 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 23, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed solid operational execution and strategic progress: Thermo Fisher delivered a strong quarter with mid-single-digit reported revenue growth, EPS growth, meaningful product launches, accretive M&A (Clario) and raised full-year guidance. Positives included strong Life Sciences Solutions and Laboratory Products performance, robust cash generation, and continued shareholder returns. Offsetting risks highlighted were low organic growth in Q1, weakness in Analytical Instruments and certain diagnostics markets (notably academic/government and China), tariff/FX headwinds, elevated leverage following the acquisition, and an inflation uncertainty placeholder. Overall, the constructive financial results and upward guidance outweighed the near-term headwinds and uncertainties.

Company Guidance

Management raised 2026 guidance to $47.3–$48.1 billion of revenue (6%–8% reported growth vs. 2025) while continuing to assume 3%–4% organic growth, and raised adjusted EPS to $24.64–$25.12 (8%–10% growth); the update incorporates Clario (adds ~$900 million to 2026 revenue and about $0.32 of EPS; Clario added $30 million and $0.01 in Q1) and, at the midpoint, the guide is ~$900M higher, ~20 bps of additional margin expansion and ~$0.37 higher adjusted EPS versus prior guidance. Management expects ~70 bps of full‑year adjusted operating margin expansion, a ~$300 million FX tailwind, net interest expense of about $660 million, an 11.5% adjusted tax rate, $1.9–$2.1 billion of net capex, free cash flow of $6.9–$7.4 billion, assumes $3 billion of share buybacks (completed) and ~ $700 million of dividends, a full‑year diluted share count of ~370–375 million, and is modeling Q2 at roughly 3% organic growth with Q2 EPS $0.25–$0.30 above Q1.

Revenue and EPS Growth

Reported revenue grew 6% year-over-year to $11.01 billion in Q1; adjusted EPS grew 6% to $5.44; GAAP EPS was $4.43, up 11%.

Adjusted Operating Income & Margins

Adjusted operating income increased 6% to $2.4 billion and adjusted operating margin was 21.8% in Q1; adjusted gross margin was 40.8%.

Raised Full-Year Guidance

Full-year revenue guidance raised to $47.3B–$48.1B (6%–8% reported growth) with assumed 3%–4% organic growth; adjusted EPS guidance raised to $24.64–$25.12 (8%–10% growth).

Successful Acquisition of Clario

Completed Clario acquisition (~$9B) in late March; Clario added $30 million of revenue and $0.01 of adjusted EPS in Q1 and increased 2026 revenue guidance by ~$900 million and EPS by ~$0.32 (net of financing) at the midpoint.

Strong Segment Performance — Life Sciences Solutions & Laboratory Products

Life Sciences Solutions reported revenue +13% (organic +1%), adjusted operating income +14%, margin 36.2% (+60 bps). Laboratory Products & Biopharma Services reported revenue +7% (organic +4%), adjusted operating income +6%.

Clinical Research Momentum and Commercial Wins

Clinical research business delivered strong revenue and authorizations growth, continued share gains and expanding pipeline; accelerated drug development offering driving differentiation.

Capital Deployment and Shareholder Returns

Repurchased $3.0 billion of shares in the quarter (total capital to shareholders ~$3.2B including dividends) and increased dividend by 10%.

Product Innovation and Strategic Partnerships

Launched multiple new products (e.g., Thermo Scientific Glacios 3 Cryo-TEM, TSQ Certis Triple Quad, Niton XL5E, Gibco CTS Compleo, FluidEase Pro) and announced strategic collaborations with NVIDIA and SHL Medical; opened Cryo-EM Drug Discovery Center.

Operational Execution & Cash Generation

Strong productivity delivered: Q1 cash flow from operations $1.2 billion and free cash flow $830 million after $370 million net capex; adjusted ROIC 11%.

Thermo Fisher (TMO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TMO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 29, 2026	2026 (Q2)	5.73 / -	5.36	―	―	―
Apr 23, 2026	2026 (Q1)	5.25 / 5.44	5.15	5.63% (+0.29)	―
Jan 29, 2026	2025 (Q4)	6.45 / 6.57	6.1	7.70% (+0.47)	―
Oct 22, 2025	2025 (Q3)	5.50 / 5.79	5.28	9.66% (+0.51)	―
Jul 23, 2025	2025 (Q2)	5.23 / 5.36	5.37	-0.19% (>-0.01)	―
Apr 23, 2025	2025 (Q1)	5.10 / 5.15	5.11	0.78% (+0.04)	―
Jan 30, 2025	2024 (Q4)	5.94 / 6.10	5.67	7.58% (+0.43)	―
Oct 23, 2024	2024 (Q3)	5.24 / 5.28	5.69	-7.21% (-0.41)	―
Jul 24, 2024	2024 (Q2)	5.12 / 5.37	5.15	4.27% (+0.22)	―
Apr 24, 2024	2024 (Q1)	4.71 / 5.11	5.03	1.59% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TMO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 23, 2026	$513.98	$466.70	-9.20%
Jan 29, 2026	$607.42	$591.58	-2.61%
Oct 22, 2025	$557.02	$566.21	+1.65%
Jul 23, 2025	$426.49	$465.48	+9.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.